The estimated Net Worth of Grace Colon is at least $663 mil dollars as of 10 August 2022. Grace Colon owns over 2,521 units of Caredx Inc stock worth over $138,770 and over the last 5 years he sold CDNA stock worth over $229,857. In addition, he makes $294,277 as Independent Director at Caredx Inc.
Grace has made over 3 trades of the Caredx Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 2,521 units of CDNA stock worth $62,546 on 10 August 2022.
The largest trade he's ever made was selling 5,179 units of Caredx Inc stock on 11 May 2022 worth over $119,169. On average, Grace trades about 699 units every 12 days since 2019. As of 10 August 2022 he still owns at least 4,864 units of Caredx Inc stock.
You can see the complete history of Grace Colon stock trades at the bottom of the page.
Dr. Grace E. Colon Ph.D. serves as Independent Director of the Company. Dr. Colón has served as President, Chief Executive Officer and Director of InCarda Therapeutics, Inc., a clinical-stage company developing therapeutics for cardiovascular conditions since 2013. In addition to her role at InCarda, Dr. Colón is also the Executive Chairman (formerly Chief Executive Officer) of ProterixBio, Inc., and serves on the board of Cocoon Biotech, Inc. Dr. Colón was a co-founder of Pyranose Biotherapeutics, a biologics discovery platform company. She was also the founding President of the Industrial Products Division at Intrexon Corporation, where she established a new division focused on leveraging synthetic biology for bioindustrial applications such as biofuels and renewable chemicals. Prior to Intrexon, she was head of Clinical Operations for Gilead Sciences, Inc., where she was responsible for global execution of clinical trials. She also created and led both the Alliance Management and Commercial Strategic Planning groups. Prior to Gilead, she was Vice President, Corporate Planning at Affymetrix Inc., where she was responsible for strategic planning and project management and where she also served as Chief Operating Officer for the International Genomics Consortium, a non-profit medical research organization focused on cancer genomics. Earlier in her career, she was a consultant with McKinsey & Co., where she served clients in healthcare, biotech, high tech and venture capital. Dr. Colón received her B.S. in chemical engineering from the University of Pennsylvania and a Ph.D. in chemical engineering from the Massachusetts Institute of Technology. Dr. Colón has also served on the boards of Paradigm Diagnostics, Inc. and PerceptiMed, Inc
As the Independent Director of Caredx Inc, the total compensation of Grace Colon at Caredx Inc is $294,277. There are 9 executives at Caredx Inc getting paid more, with Peter Maag having the highest compensation of $8,855,740.
Grace Colon is 53, he's been the Independent Director of Caredx Inc since 2019. There are 6 older and 9 younger executives at Caredx Inc. The oldest executive at Caredx Inc is Ralph Snyderman, 80, who is the Independent Director.
Grace's mailing address filed with the SEC is C/O VOYAGER THERAPEUTICS, INC., 75 HAYDEN AVENUE, LEXINGTON, MA, 02421.
Over the last 10 years, insiders at Caredx Inc have traded over $60,271,359 worth of Caredx Inc stock and bought 1,726,634 units worth $9,072,700 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Neil Gagnon, ePeter Maag. On average, Caredx Inc executives and independent directors trade stock every 17 days with the average trade being worth of $615,506. The most recent stock trade was executed by Alexander L Johnson on 20 August 2024, trading 61,023 units of CDNA stock currently worth $1,432,820.
caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos
Caredx Inc executives and other stock owners filed with the SEC include: